The expert committee nominated by the Central Drugs Standards Control Organisation has recommended the use of the Oxford University-AstraZeneca vaccine Covishield, to be manufactured by Serum Institute, and Bharat Biotech-ICMR’s Covaxin for emergency use. Although dry runs have been conducted for the vaccine delivery, plans for a speedy rollout are nowhere in evidence. Yet, such meticulous planning is exactly what is needed if the vaccine is to be effective in building herd immunity and offering a return to normal economic life, says the top edit here.
Other views today examine the stock-market surge, solutions to the huge backlog in